• All sections
  • C - Chemistrymetallurgy
  • C07D - Heterocyclic compounds
  • C07D 211/34 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Patent holdings for IPC class C07D 211/34

Total number of patents in this class: 435

10-year publication summary

26
31
21
27
33
29
31
38
19
15
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

Principal owners for this class

Owner
All patents
This class
Incyte Corporation
1020
15
Incyte Holdings Corporation
655
13
Zevra Therapeutics, Inc.
99
13
Novartis AG
10856
11
Biogen MA Inc.
894
11
Boehringer Ingelheim International GmbH
4665
8
AstraZeneca AB
2923
7
Massachusetts Institute of Technology
10041
7
Takeda Pharmaceutical Company Limited
2714
7
Nocion Therapeutics, Inc.
42
7
ReNAgade Therapeutics Management Inc.
44
7
The General Hospital Corporation
4724
6
The Broad Institute, Inc.
1800
6
Guangzhou Innocare Pharma Tech Co., Ltd.
12
6
Praxis Precision Medicines, Inc.
174
6
ChemoCentryx, Inc.
386
5
AstraZeneca UK Limited
650
4
Janssen Pharmaceutica N.V.
3392
4
The Regents of the University of Michigan
4689
4
Astellas Pharma Inc.
1086
4
Other owners 284